Yehuda Kolander's scientific contributions

Publications (2)

Article
Neoadjuvant chemotherapy for osteosarcoma is the standard of care, but there is still confusion regarding the best chemotherapy regimen and the optimal intensity. This retrospective study intends to evaluate whether there is a clear correlation between the chemotherapy dose intensity (DI) and the percentage of tumor necrosis, the risk of tumor recu...

Citations

... With the development of new printing technologies and materials, 3D printed models can now be used for pre-operative surgical simulations and directly in the OR as intra-operative guides [5][6][7][8]. In patients undergoing oncologic resections, 3D printed cutting jigs and drilling guides, can help ensure both adequate margins and preoperatively planned margins, which often correspond to custom-made implants [9]. 3D printing patient- ...
... 14 Saeter et al. demonstrated that Huvos I patients had lower H24 and H48 methotrexate levels, 11 Delepine et al. adapted chemotherapy doses to the excretory potential of each patient 15 increasing thus the tumor necrosis, and Bacci identified the 700 mmol/l Methotrexate level to be linked to a higher complete tumor necrosis rate. 16 On the other hand, Eselgrim et al. did not found any statistical relation between 200 days dose-intensity of chemotherapy and survival outcome, nor did the European Osteosarcoma Intergroup or Kushnir et al. [17][18][19] These results suggest that patient prognosis is not threatened by inevitable treatments delays. Our patients received neoadjuvant chemotherapy in due time (median duration time of 12 weeks) and mostly accomplished all their scheduled cures (median number of 7 + 2 cures for methotrexate-treated patients and 3 + 1 for Adriamycin-Cisplatinum-Ifosfamide-treated patients). ...